Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients
| Autor: | R. Bonanthaya, B.K.M. Reddy, K.G. Babu, Kamalaksha Shenoy, M. S. Vidyasagar, V. Lokesh, Loknatha, Nanjundappa, Ashok M. Shenoy, Jayarama K. Shetty, Krishna Prasad, C.R. Tanvir Pasha, T. Naveen, Bindhu Joseph, P.P. Bapsy |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty genetic structures medicine.medical_treatment Population Antineoplastic Agents Antibodies Monoclonal Humanized Internal medicine medicine Nimotuzumab Humans Epidermal growth factor receptor education Adverse effect Aged education.field_of_study biology business.industry Head and neck cancer Middle Aged medicine.disease Combined Modality Therapy Survival Analysis Surgery Radiation therapy ErbB Receptors Head and Neck Neoplasms Monoclonal biology.protein Carcinoma Squamous Cell Female Oral Surgery business Chemoradiotherapy medicine.drug |
| Zdroj: | Oral oncology. 50(5) |
| ISSN: | 1879-0593 |
| Popis: | Summary Objective Overexpression of epidermal growth factor receptor (EGFR) in many cancers makes it an attractive therapeutic target. This study evaluated the clinical utility of nimotuzumab, a monoclonal anti-EGFR antibody, used concurrently with radiotherapy (RT) and chemoradiotherapy (CRT) in squamous cell carcinoma of the head and neck (SCCHN). Methods This open-label study randomized 92 treatment-naive patients (1:1) with advanced SCCHN into chemoradiation (CRT ± nimotuzumab) or radiation (RT ± nimotuzumab) group by investigator’s discretion; these were further randomized into CRT + nimotuzumab or CRT and RT + nimotuzumab or RT groups, respectively. Treatment included 6 cycles each of cisplatin (50 mg/week), nimotuzumab (200 mg/week), and RT (total dose, 60–66 Gy). Response (tumor size reduction) was assessed at Month 6 post-treatment and survival, at Month 60. Results Forty and 36 patients in the chemoradiation and radiation groups, respectively (intent-to-treat population) were evaluated. Overall response at Month 6 post-treatment was 100% with CRT + nimotuzumab, 70% with CRT, 76% with RT + nimotuzumab, and 37% with RT. At Month 60, overall survival was 57% with CRT + nimotuzumab, 26% with CRT ( P = 0.03), 39% with RT + nimotuzumab, and 26% with RT ( P > 0.05). Median overall survival was not reached for CRT + nimotuzumab; it was 21.94 months for CRT ( P = 0.0078), 14.36 months for RT + nimotuzumab, and 12.78 months for RT ( P = 0.45). Risk of death was 64% lower with CRT + nimotuzumab than with CRT (95%CI: 0.37, 1.56), and 24% lower with RT + nimotuzumab than with RT (95%CI: 0.16, 0.79). Thus nimotuzumab was safe and well tolerated with few mild to moderate self-limiting adverse events. Conclusion Concurrent use of nimotuzumab with CRT/RT is safe and provides long-term survival benefit. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect